CFDE Data Portal | Search FRG1FP

	Label	Description
	FRG1FP Gene (Entity type)	ENSG00000303605 - FSHD region gene 1 family member F, pseudogene
	GSE226249 pirfenidone HL 2 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 0 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE95077 amiloride 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE121425 GSE121426 LSD1 inhibition SET-2 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE149768 hypoxanthine 3 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE48812 sulforaphane 2 v 10 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE179235 MEK NRAS inhibition 0 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE102505 tunicamycin 6 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 7 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS

FRG1FP

ENSG00000303605 - FSHD region gene 1 family member F, pseudogene

GSE226249 pirfenidone HL 2 v 1 human up

A Gene Set from LINCS

GSE195663 cisplatin 0 v 3 human up

A Gene Set from LINCS

GSE95077 amiloride 1 v 0 human up

A Gene Set from LINCS

GSE121425 GSE121426 LSD1 inhibition SET-2 2 v 0 human up

A Gene Set from LINCS

GSE149768 hypoxanthine 3 v 1 human up

A Gene Set from LINCS

GSE48812 sulforaphane 2 v 10 human dn

A Gene Set from LINCS

GSE179235 MEK NRAS inhibition 0 v 7 human dn

A Gene Set from LINCS

GSE102505 tunicamycin 6 v 3 human up

A Gene Set from LINCS

GSE195663 cisplatin 7 v 3 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.